The Tumor Microenvironment in Renal Cell Cancer

Overview

Journal Curr Opin Oncol

Specialty Oncology

Date 2019 Apr 16

PMID 30985497

Citations 28

Authors

James W Mier

Affiliations

Soon will be listed here.

Abstract

Purpose Of Review: In addition to the provision of nutrients and growth factors that facilitate tumor cell proliferation and metastasis, the tumor microenvironment (MEV) restricts immune surveillance of tumor-associated antigens and limits the efficacy of immune checkpoint inhibitors, tumor vaccines, and other immune therapies. This review will focus on the immunosuppressive mechanisms operative within the tumor MVE of renal cell carcinoma.

Recent Findings: Several of the immunosuppressive mechanisms within the tumor MEV have been identified and are potentially druggable. Clinical trials with agents that target several of these inhibitory pathways are currently underway.

Summary: Although renal cell carcinoma is one of several tumor types responsive to immune checkpoint inhibitors, the effectiveness of these agents is likely to be limited by the various tumor-infiltrating bone marrow-derived myeloid cells that comprise the MEV. Several strategies to combat the recruitment of these cells into tumor tissue or to neutralize their immunosuppressive function have shown encouraging results in animal tumor models and clinical trials.

Citing Articles

Identification and validation of prognostic biomarkers in ccRCC: immune-stromal score and survival prediction.

Lyu F, Zhong Y, He Q, Xiao W, Zhang X BMC Cancer. 2025; 25(1):148.

PMID: 39871215 PMC: 11771106. DOI: 10.1186/s12885-025-13534-0.

The potential value of dual-energy CT radiomics in evaluating CD8, CD163 and αSMA cells in the tumor microenvironment of clear cell renal cell carcinoma.

Li R, Bing X, Su X, Zhang C, Sun H, Dai Z Clin Transl Oncol. 2024; 27(2):716-726.

PMID: 39083142 DOI: 10.1007/s12094-024-03637-8.

Immunotherapy Applications for Thymine Dimers and WT1 Antigen in Renal Cancers: A Comparative Statistical Analysis.

Latcu S, Bardan R, Cumpanas A, Barbos V, Baderca F, Gaje P J Pers Med. 2024; 14(6).

PMID: 38929778 PMC: 11205122. DOI: 10.3390/jpm14060557.

BAG3 as a novel prognostic biomarker in kidney renal clear cell carcinoma correlating with immune infiltrates.

Gong B, Huang Y, Wang Z, Wan B, Zeng Y, Lv C Eur J Med Res. 2024; 29(1):93.

PMID: 38297320 PMC: 10832118. DOI: 10.1186/s40001-024-01687-w.

Mechanisms of tyrosine kinase inhibitor resistance in renal cell carcinoma.

Sweeney P, Suri Y, Basu A, Koshkin V, Desai A Cancer Drug Resist. 2024; 6(4):858-873.

PMID: 38239394 PMC: 10792482. DOI: 10.20517/cdr.2023.89.

References

Li B, Qiu B, Lee D, Walton Z, Ochocki J, Mathew L . Fructose-1,6-bisphosphatase opposes renal carcinoma progression. Nature. 2014; 513(7517):251-5. PMC: 4162811. DOI: 10.1038/nature13557. View

Sitohy B, Nagy J, Dvorak H . Anti-VEGF/VEGFR therapy for cancer: reassessing the target. Cancer Res. 2012; 72(8):1909-14. PMC: 3335750. DOI: 10.1158/0008-5472.CAN-11-3406. View

Groth C, Hu X, Weber R, Fleming V, Altevogt P, Utikal J . Immunosuppression mediated by myeloid-derived suppressor cells (MDSCs) during tumour progression. Br J Cancer. 2018; 120(1):16-25. PMC: 6325125. DOI: 10.1038/s41416-018-0333-1. View

Cao Y, Zhang Z, Zhou M, Elson P, Rini B, Aydin H . Pericyte coverage of differentiated vessels inside tumor vasculature is an independent unfavorable prognostic factor for patients with clear cell renal cell carcinoma. Cancer. 2012; 119(2):313-24. DOI: 10.1002/cncr.27746. View

Liu J, Deng W, Chen L, Li Y, Wu L, Ma S . Inhibition of JAK2/STAT3 reduces tumor-induced angiogenesis and myeloid-derived suppressor cells in head and neck cancer. Mol Carcinog. 2017; 57(3):429-439. DOI: 10.1002/mc.22767. View

Rosenberg S . IL-2: the first effective immunotherapy for human cancer. J Immunol. 2014; 192(12):5451-8. PMC: 6293462. DOI: 10.4049/jimmunol.1490019. View

Lawrence M, Stojanov P, Polak P, Kryukov G, Cibulskis K, Sivachenko A . Mutational heterogeneity in cancer and the search for new cancer-associated genes. Nature. 2013; 499(7457):214-218. PMC: 3919509. DOI: 10.1038/nature12213. View

Delage B, Fennell D, Nicholson L, McNeish I, Lemoine N, Crook T . Arginine deprivation and argininosuccinate synthetase expression in the treatment of cancer. Int J Cancer. 2010; 126(12):2762-72. DOI: 10.1002/ijc.25202. View

Fu Q, Xu L, Wang Y, Jiang Q, Liu Z, Zhang J . Tumor-associated Macrophage-derived Interleukin-23 Interlinks Kidney Cancer Glutamine Addiction with Immune Evasion. Eur Urol. 2018; 75(5):752-763. DOI: 10.1016/j.eururo.2018.09.030. View

10.

Snyder A, Makarov V, Merghoub T, Yuan J, Zaretsky J, Desrichard A . Genetic basis for clinical response to CTLA-4 blockade in melanoma. N Engl J Med. 2014; 371(23):2189-2199. PMC: 4315319. DOI: 10.1056/NEJMoa1406498. View

11.

Choueiri T, Larkin J, Oya M, Thistlethwaite F, Martignoni M, Nathan P . Preliminary results for avelumab plus axitinib as first-line therapy in patients with advanced clear-cell renal-cell carcinoma (JAVELIN Renal 100): an open-label, dose-finding and dose-expansion, phase 1b trial. Lancet Oncol. 2018; 19(4):451-460. DOI: 10.1016/S1470-2045(18)30107-4. View

12.

Motzer R, Escudier B, Mcdermott D, George S, Hammers H, Srinivas S . Nivolumab versus Everolimus in Advanced Renal-Cell Carcinoma. N Engl J Med. 2015; 373(19):1803-13. PMC: 5719487. DOI: 10.1056/NEJMoa1510665. View

13.

Motzer R, Hutson T, Cella D, Reeves J, Hawkins R, Guo J . Pazopanib versus sunitinib in metastatic renal-cell carcinoma. N Engl J Med. 2013; 369(8):722-31. DOI: 10.1056/NEJMoa1303989. View

14.

Hornyak L, Dobos N, Koncz G, Karanyi Z, Pall D, Szabo Z . The Role of Indoleamine-2,3-Dioxygenase in Cancer Development, Diagnostics, and Therapy. Front Immunol. 2018; 9:151. PMC: 5797779. DOI: 10.3389/fimmu.2018.00151. View

15.

Gross M, Demo S, Dennison J, Chen L, Chernov-Rogan T, Goyal B . Antitumor activity of the glutaminase inhibitor CB-839 in triple-negative breast cancer. Mol Cancer Ther. 2014; 13(4):890-901. DOI: 10.1158/1535-7163.MCT-13-0870. View

16.

Najjar Y, Rayman P, Jia X, Pavicic Jr P, Rini B, Tannenbaum C . Myeloid-Derived Suppressor Cell Subset Accumulation in Renal Cell Carcinoma Parenchyma Is Associated with Intratumoral Expression of IL1β, IL8, CXCL5, and Mip-1α. Clin Cancer Res. 2016; 23(9):2346-2355. PMC: 5411325. DOI: 10.1158/1078-0432.CCR-15-1823. View

17.

Rizvi N, Hellmann M, Snyder A, Kvistborg P, Makarov V, Havel J . Cancer immunology. Mutational landscape determines sensitivity to PD-1 blockade in non-small cell lung cancer. Science. 2015; 348(6230):124-8. PMC: 4993154. DOI: 10.1126/science.aaa1348. View

18.

Orillion A, Hashimoto A, Damayanti N, Shen L, Adelaiye-Ogala R, Arisa S . Entinostat Neutralizes Myeloid-Derived Suppressor Cells and Enhances the Antitumor Effect of PD-1 Inhibition in Murine Models of Lung and Renal Cell Carcinoma. Clin Cancer Res. 2017; 23(17):5187-5201. PMC: 5723438. DOI: 10.1158/1078-0432.CCR-17-0741. View

19.

Bex A, Etto T, Vyth-Dreese F, Blank C, Griffioen A . Immunological heterogeneity of the RCC microenvironment: do targeted therapies influence immune response?. Curr Oncol Rep. 2012; 14(3):230-9. DOI: 10.1007/s11912-012-0229-9. View

20.

Thompson R, Dong H, Lohse C, Leibovich B, Blute M, Cheville J . PD-1 is expressed by tumor-infiltrating immune cells and is associated with poor outcome for patients with renal cell carcinoma. Clin Cancer Res. 2007; 13(6):1757-61. DOI: 10.1158/1078-0432.CCR-06-2599. View